Secretin Acetate

Secretin acetate is an important endogenous polypeptide regulator widely distributed in the human body, with specific receptors expressed in multiple key brain regions of the central nervous system. This anatomical and molecular basis enables it to participate in the regulation of central neural activity and play a potential regulatory role in neurological function.

For a long time, relevant research on it has been continuously expanded, and its potential value in neurological diseases has gradually attracted widespread attention. This article focuses on the effects and specific mechanisms of this drug in two common neurological disorders-autism spectrum disorder and Parkinson's disease, systematically elaborates on its intervention effect, potential neural regulatory mechanism, and existing research limitations, aiming to supplement the understanding of secretin's neural regulatory function and provide theoretical references for related research in the field of neurological diseases.

 

Our Products Form

 

Secretin COA

Secretin acetate and its specific receptors are distributed in multiple brain regions of the central nervous system, providing an anatomical basis for their potential involvement in the regulation of neural functions. Researchers have conducted extensive basic and clinical studies on the application of this peptide in two neurological disorders: autism spectrum disorder and Parkinson's disease. Both its effects and underlying mechanisms have yielded phased findings, and all related studies are conducted independently of its other physiological regulatory functions such as digestion and metabolism.

(I)Regulation of Neural Electrical Activity in Key Functional Brain Regions via Central Nervous System-Specific Receptors

Secretin-specific receptors are widely distributed throughout the central nervous system and are expressed in key brain regions involved in regulating social behavior, cognitive function, and emotional responses, such as the prefrontal cortex, amygdala, and hippocampus. It can reach these brain regions via the bloodstream or specific transport pathways, bind to their specific receptors, and subsequently modulate neuronal firing frequency, signal transmission strength, and synchronization in the corresponding regions. Patients with autism spectrum disorder often exhibit abnormal neural electrical activity in these brain regions. The regulatory role of it aims to correct such disrupted neuroelectrophysiological activity, providing a neuroelectrophysiological foundation for improving social, emotional, and cognitive functions.

(II)Maintenance of Metabolic and Release Balance of Key Central Neurotransmitters

Imbalance in central neurotransmitters is a significant pathophysiological mechanism in autism spectrum disorder. It can participate in regulating various physiological processes of key neurotransmitters within the central nervous system, including their synthesis, release, presynaptic reuptake, and degradation. Through this regulatory role, Secretin acetate helps maintain a dynamic balance between excitatory and inhibitory neurotransmitters, thereby improving abnormal neural signal transmission caused by neurotransmitter dysregulation. Enhanced stability in neural signal transmission can help alleviate core symptoms such as stereotyped behaviors, emotional dysregulation, and social withdrawal in patients, representing an important neurotransmitter-level mechanism for its potential therapeutic effects.

(III)Modulation of Neural Synaptic Plasticity and Remodeling of Abnormal Neural Circuits

Neural synaptic plasticity is the fundamental basis for establishing connections between neurons and forming functional neural circuits. Patients with autism spectrum disorder commonly exhibit abnormal synaptic development and disrupted neural circuit connections. Secretin can participate in regulating the formation, maturation, and pruning processes of neural synapses, thereby enhancing synaptic plasticity. By optimizing synaptic structure and function, this helps repair abnormal neural circuit connections and reconstruct neural pathways related to social interaction, language cognition, and emotional regulation. This mechanism provides theoretical support for the potential therapeutic role of it from the perspective of neural development and neural circuit remodeling, which is also a core reason for its inclusion in autism-related scientific research.

01.Neuroprotective Effects in Cellular Experiments (In Vitro Validation)

In in vitro cellular experiments, researchers primarily utilize Parkinson's disease-related neuronal cell models (such as dopaminergic neuronal cell lines or primary dopaminergic neurons) and simulate the pathological processes of neuronal damage and apoptosis in Parkinson's disease by adding classic pathogenic inducers like MPTP or 6-OHDA. Secretin intervention is then administered. Experimental results show that it significantly enhances the viability of damaged neurons, reduces neuron morphological abnormalities induced by pathogenic factors (such as neurite fragmentation and soma shrinkage), and markedly decreases the proportion of functional dopaminergic neurons undergoing apoptosis. This is specifically manifested as reduced expression of apoptosis-related proteins and decreased formation of apoptotic bodies, effectively slowing the damage process of dopaminergic neurons. Furthermore, some studies have found that it can slightly promote the nutritional metabolism of damaged neurons, enhancing their tolerance to pathogenic stimuli, thereby providing robust in vitro theoretical support for subsequent in vivo experiments.

02.Neuroprotective Effects in Animal Experiments (In Vivo Validation)

 

In in vivo animal experiments, mice or rats are typically used to construct Parkinson's disease models (such as MPTP-induced mouse models or 6-OHDA stereotactic injection rat models). These models accurately simulate the core pathological features of human Parkinson's disease, including degenerative lesions of dopaminergic neurons, motor dysfunction, and the formation of abnormal pathological aggregates in the brain. After administering Secretin intervention to model animals (commonly via intraperitoneal injection, intravenous injection, or intracerebroventricular injection), long-term observation and testing reveal that it exerts clear neuroprotective effects: First, it effectively slows the degenerative process of dopaminergic neurons in the substantia nigra pars compacta of the midbrain, reduces neuronal loss, increases the levels of dopamine and its metabolites in the brain, and improves the conduction function of dopaminergic neural pathways.

Second, it significantly alleviates motor dysfunction in model animals, specifically manifested as reduced tremor frequency and amplitude in limbs, improved symptoms of bradykinesia, and enhanced behavioral scores in tests such as the pole test, rotarod test, and balance beam test, helping model animals partially regain autonomous motor abilities. Third, it mitigates local abnormal pathological reactions in the central nervous system, reduces the aggregation of inflammatory factors in the brain, inhibits the initial accumulation of abnormal pathological proteins, alleviates microenvironmental disturbances around neurons, and provides relatively stable conditions for the survival of dopaminergic neurons.

03.Molecular and cellular level neuroprotective mechanisms

 

Activation of Anti-Damage Signaling Pathways to Block Dopaminergic Neuronal Apoptosis

This is the core molecular mechanism through which secretin exerts its neuroprotective effects in Parkinson's disease. In the pathological progression of Parkinson's disease, abnormal apoptosis of dopaminergic neurons in the substantia nigra pars compacta of the midbrain is a central aspect of disease development and a key factor leading to motor dysfunction in patients. It can cross the blood-brain barrier via the bloodstream and precisely bind to specific receptors on the surface of dopaminergic neuronal cell membranes. This activation triggers multiple intracellular anti-damage and anti-apoptotic signaling pathways in neurons, with the PI3K/Akt and ERK1/2 signaling pathways being its primary regulatory targets. Once activated, these pathways precisely modulate the activity states of various downstream functional proteins through phosphorylation modifications.

On one hand, they significantly enhance the stress resistance and damage tolerance of dopaminergic neurons themselves, strengthening their ability to withstand exogenous pathogenic inducers such as MPTP and 6-OHDA and reducing direct neuronal damage caused by pathogenic factors. On the other hand, they directly block the transmission chains of apoptotic signals, inhibit the transcriptional activation and expression of apoptosis-related genes, and reduce the synthesis and activation of apoptosis-related proteins such as the caspase family. This effectively suppresses excessive apoptosis of dopaminergic neurons, maintains their normal morphological structure and physiological conduction functions, and slows the pathological progression of Parkinson's disease.

 

Inhibition of Neuroglial Cell Overactivation to Optimize the Central Nervous System Microenvironment

Abnormal activation of neuroglial cells in the central nervous system is a significant pathological factor exacerbating dopaminergic neuronal damage in Parkinson's disease. During the pathological progression of Parkinson's disease, microglia and astrocytes in the brain become abnormally activated, entering a state of overactivation. These activated glial cells excessively secrete neurotoxic inflammatory mediators such as TNF-α, IL-1β, and NO, triggering localized chronic inflammatory responses in the central nervous system. This disrupts the microenvironment homeostasis required for dopaminergic neuronal survival and accelerates neuronal damage and loss. Through specific molecular regulatory actions, Secretin significantly inhibits the overactivation of microglia and astrocytes, reducing the secretion and release of their neurotoxic inflammatory mediators.

Simultaneously, it lowers the activation levels of inflammation-related signaling pathways such as NF-κB, alleviating localized chronic inflammatory responses in the central nervous system and mitigating the persistent damage caused by inflammatory mediators to dopaminergic neurons. Additionally, secretin acetate can modulate astrocyte function to promote the secretion of neurotrophic substances such as brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF). This provides ample nutritional support for the repair and survival of dopaminergic neurons, further optimizing the central nervous system microenvironment and laying a solid foundation for neuronal protection.

Regulation of Autophagy Pathways to Clear Abnormal Accumulation of Pathological Substances in the Brain

Abnormal folding, aggregation, and formation of Lewy bodies by α-synuclein in the brain is one of the most typical pathological features of Parkinson's disease. These abnormally accumulated pathological substances continuously damage dopaminergic neurons, hinder normal neural signal transmission, and further accelerate the decline of neural function. Existing basic experimental studies indicate that it can precisely regulate the activity of autophagy pathways within dopaminergic neurons, significantly enhancing the expression and activity levels of autophagy-related functional proteins (such as Beclin-1 and LC3). This promotes the maintenance of the cellular autophagy process at a normal physiological level. Once moderately activated, the autophagy pathway can specifically recognize, encapsulate, and degrade abnormally accumulated α-synuclein and damaged organelles in the brain.

This reduces the deposition and accumulation of such harmful substances within neurons, thereby alleviating their persistent toxic damage to dopaminergic neurons and slowing the degenerative changes in neural function. This mechanism serves as an important supplement to Secretin's neuroprotective effects in Parkinson's disease, further refining its multidimensional synergistic protective molecular logic.

Hot Tags: secretin acetate, China secretin acetate manufacturers, suppliers, Botulinum Toxin Injection 100iu, Nad Capsule, Nad Peptide Injection, Nad Tablet, BPC 157 Peptide Cream, BPC 157 Peptide Capsules